CA
NZ
UK
AU
IND
US
Sagimet Biosciences Inc. (NASDAQ: SGMT) has announced a narrower earnings loss for the first quarter of 2026, posting earnings per share (EPS) of $-0.33, surpassing analyst expectations of $-0.38. This result marks a key point in the company's financial performance as it indicates improved …
Sonova experienced a notable increase in its stock price following the announcement of its latest earnings report, which effectively underscores the company's strong position within the hearing care market. The results reflect not only solid financial performance but also strategic advancements, positioning Sonova as …
The urgency surrounding the Ebola outbreak has placed a major healthcare company under heightened scrutiny as it prepares to explore avenues for an experimental vaccine strategy aimed at health workers. With the stock recently trading at $110.46 following a minor pre-market decline, the looming …
Eli Lilly and Co. (NYSE: LLY) saw its shares slip 0.5% to $1169.83 in pre-market trading following mixed sentiment over President Donald Trump's recent praise for the company. At a public event, Trump lauded Lilly's plans for a substantial $3.5 billion investment into a …
HCA Healthcare Inc. (NYSE: HCA) has seen its stock rise by 0.5% in pre-market trading, priced at $374.99, following the announcement of its latest earnings report. This positive earnings surprise may indicate HCA's strong operational performance, even as it faces challenges within the healthcare …
Agilon Health, Inc. (NYSE: AGL) has announced a significant leadership change as Chief Technology Officer Girish Venkatachaliah is set to depart from the firm on August 1, 2026. This decision comes as part of a series of executive transitions, marking the company's 13th such …
Abbott Laboratories has showcased strong performance through its second-quarter results, reporting a 13% rise in revenue year-over-year to reach $12.6 billion, outperforming forecasts of $12.52 billion. While the broader market has weighed on Abbott's stock, which has declined by 19% year-to-date, these results solidify …
Niki BioSolutions, Inc. (NASDAQ: NIKI) shares closed up 8% at $9.54 after the company, formerly known as Aptorum Group Limited, finalized its all-stock business combination with DiamiR Biosciences Corp.
Palvella Therapeutics (NASDAQ: PVLA) shares closed up 16% at $143.94 after LifeSci Capital reaffirmed its Buy rating and $225 price target, despite the FDA's recent denial of Breakthrough Therapy Designation (BTD) for QTORIN in cutaneous vascular malformations (CVMs).
Calidi Biotherapeutics (NYSE: CLDI) shares closed down 14% at $0.10 after the company disclosed a 1-for-16 reverse stock split scheduled to take effect on July 31, 2026.
Please wait processing your request...